Technology Brief -- Dura Pharmaceuticals Inc.:
   FDA Panel Deals Setback
   To Pentyde Nasal Spray
"It is certainly our belief that trials conducted by the
company demonstrated both safety and efficacy," said Cam L.
Garner, Dura president and chief executive officer. "It is
the company's intent to confer with the FDA and then decide
how to proceed to gain marketing approval for Pentyde."
   Pentyde is a treatment for seasonal rhinitis, which
affects 22 million people in the U.S. each year. Dura is
based in San Diego.